Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Stock Institutional Investors Like

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Logo

Sentiment for Regeneron Pharmaceuticals Inc (NASDAQ:REGN)

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) institutional sentiment increased to 1.96 in Q1 2019. Its up 0.83, from 1.13 in 2018Q4. The ratio is positive, as 319 investment professionals started new and increased holdings, while 163 trimmed and sold equity positions in Regeneron Pharmaceuticals Inc. The investment professionals in our partner’s database now own: 71.25 million shares, down from 77.33 million shares in 2018Q4. Also, the number of investment professionals holding Regeneron Pharmaceuticals Inc in their top 10 holdings decreased from 7 to 5 for a decrease of 2. Sold All: 34 Reduced: 129 Increased: 216 New Position: 103.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, makes, and commercializes medicines for the treatment of serious medical conditions worldwide. The company has market cap of $33.76 billion. The Company’s products include EYLEA injection for the treatment of neovascular age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion; Praluent injection, an adjunct to diet and tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and ARCALYST injection for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and childrenÂ’s. It has a 16.79 P/E ratio. It also markets Kevzara injection for the treatment of rheumatoid arthritis in adults; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer.

The stock increased 0.65% or $1.96 during the last trading session, reaching $302.22. About 678,343 shares traded. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has declined 17.97% since August 8, 2018 and is downtrending. It has underperformed by 17.97% the S&P500.

Mcdonald Capital Investors Inc Ca holds 4.6% of its portfolio in Regeneron Pharmaceuticals, Inc. for 134,985 shares. Sustainable Growth Advisers Lp owns 920,422 shares or 4.18% of their US portfolio. Moreover, Polen Capital Management Llc has 3.44% invested in the company for 1.60 million shares. The Michigan-based Usa Financial Portformulas Corp has invested 3.34% in the stock. Premier Asset Management Llc, a Illinois-based fund reported 33,911 shares.

Since January 1, 0001, it had 0 buys, and 1 sale for $54.04 million activity.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Ratings Coverage

Ratings analysis reveals 25% of Regeneron Pharmaceuticals’s analysts are positive. Out of 4 Wall Street analysts rating Regeneron Pharmaceuticals, 1 give it “Buy”, 0 “Sell” rating, while 3 recommend “Hold”. The lowest target is $353 while the high is $487. The stock’s average target of $425.20 is 40.69% above today’s ($302.22) share price. REGN was included in 15 notes of analysts from February 22, 2019. The firm earned “Hold” rating on Monday, March 18 by Cantor Fitzgerald. Cowen & Co maintained Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on Monday, February 25 with “Hold” rating. The stock has “Neutral” rating by Guggenheim on Friday, February 22. The firm has “Buy” rating by Piper Jaffray given on Monday, February 25. As per Monday, March 18, the company rating was maintained by Piper Jaffray. The stock of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has “Hold” rating given on Friday, June 21 by Cowen & Co. The rating was maintained by Cantor Fitzgerald on Thursday, March 7 with “Hold”.

More notable recent Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) news were published by: which released: “April 26th Options Now Available For Regeneron Pharmaceuticals (REGN) – Nasdaq” on March 11, 2019, also with their article: “Nasdaq 100 Movers: TSLA, REGN – Nasdaq” published on May 21, 2019, published: “Is Intellia Therapeutics a Buy? – Yahoo Finance” on July 31, 2019. More interesting news about Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) were released by: and their article: “The Daily Biotech Pulse: Sanofi’s Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering – Benzinga” published on August 06, 2019 as well as‘s news article titled: “Company News for Aug 7, 2019 – Nasdaq” with publication date: August 07, 2019.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.